Broncus Holding Corp (2216) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Broncus Holding Corp HK$0.28, price HK$0.74, upside -61.9%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Broncus Holding Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range HK$0.4600 – HK$15.10 · fair‑value band HK$0.1900 – HK$0.3600 · the HK$0.7350 price screens above the HK$0.2800 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Broncus Holding in your weekly email
Every Wednesday you see whether Broncus Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally.
Show more
Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; BroncTarget Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of acute COPD exacerbation management; H-Marker, a pulmonary surgical marker that can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, thoracic surgery staining location, etc.; and BroncTru, a disposable transbronchoscopic dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath, and for used to dilate the target lung tissue of the bronchial tree; BioStarNeedle, a single use ultrasound-guided needle for retrieval of tissue samples; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. The company was incorporated in 2012 and is headquartered in Hangzhou, China.
Stock analysis
Broncus Holding Corp (2216) currently trades at HK$0.7350, while our model-based Fair Value estimate is HK$0.2800, 61.9% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: HK$0.1900 (bear) to HK$0.3600 (bull), the price of HK$0.7350 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Broncus Holding Corp reported revenue of 174K CNY in FY2025 versus 10.9M CNY in FY2021, a compound −64.4%/yr. Reported net income was −17.9M CNY in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 78% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −62%, 2216 screens richer than that median.
Fair Value models
Bear HK$0.1900Fair Value HK$0.2800Bull HK$0.3600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−97.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−73.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−44.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−47.2%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−648.5% (2020) → −14,017.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 354 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−61.9% · Bottom 25%
Profitability
Return on assets−9.2% · Below median
Growth and dividend
Revenue growth−55.4% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.30× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 4
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 8
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Broncus Holding Corp (2216) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.2800 versus a price of HK$0.7350, about −62% upside (overvalued).
What is the fair value of 2216?
Our model-based fair value for Broncus Holding Corp is HK$0.2800 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.7350.
What is the quality score of 2216?
Broncus Holding Corp has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Broncus Holding Corp (2216)?
Our model-based price target is the fair value of HK$0.2800 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.1900, optimistic scenario HK$0.3600. It is a calculation from audited fundamentals, not an analyst target.
What is the Broncus Holding Corp stock forecast for 2026?
Our models put fair value at HK$0.2800, about −62% upside versus a price of HK$0.7350 (overvalued). Cautious scenario HK$0.1900, optimistic scenario HK$0.3600. The calculation is refreshed regularly with new filings.
What is the revenue of Broncus Holding Corp (2216)?
Broncus Holding Corp reported trailing-twelve-month revenue of about 174K CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Broncus Holding Corp (2216)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Broncus Holding Corp it is HK$0.2800 per share (as of Sep 27, 2026), against a price of HK$0.7350. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Broncus Holding Corp stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2216 trades above its calculated fair value: price HK$0.7350, fair value HK$0.2800, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2216?
No. The price is what the market pays today (HK$0.7350); the fair value is what the company's own numbers justify (HK$0.2800). For Broncus Holding Corp the two are HK$0.4550 per share apart. That gap is exactly why we show both numbers side by side.
How much is Broncus Holding Corp worth?
The market values Broncus Holding Corp at about HK$356M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.7350; our models calculate a fair value of HK$0.2800 per share.
What do the bullish and bearish scenarios say about 2216?
Our models span a range for Broncus Holding Corp: cautious scenario HK$0.1900, base HK$0.2800, optimistic HK$0.3600 per share (as of Sep 27, 2026, price HK$0.7350). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Broncus Holding Corp (2216)?
Balance-sheet figures for Broncus Holding Corp (as of Sep 27, 2026): return on equity −11.2%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 2216 from its 52-week high?
Broncus Holding Corp trades at HK$0.7350, about 78% below its 52-week high of HK$3.36 and 31% above the low of HK$0.5600 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.2800 is for.
Which stocks are comparable to Broncus Holding Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Broncus Holding Corp stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.7350, calculated fair value HK$0.2800 (−62%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2216 calculated?
We run Broncus Holding Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.2800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Broncus Holding Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Broncus Holding Corp (2216)?
The closing price on Sep 30, 2026 was HK$0.7350. Our model-based fair value is HK$0.2800, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Broncus Holding Corp right now?
The price sits above even our optimistic bull case (HK$0.3600). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.1900 to HK$0.3600) leaves room in how you read the outcome.
Key figures of Broncus Holding Corp
How large is the market capitalisation of Broncus Holding Corp (2216)?
The market capitalisation of Broncus Holding Corp is HK$356M (≈ $45.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Broncus Holding Corp (2216)?
Earnings per share at Broncus Holding Corp are HK$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Broncus Holding Corp (2216)?
The return on equity (ROE) of Broncus Holding Corp is −11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Broncus Holding Corp (2216)?
On an EBIT basis the return on assets of Broncus Holding Corp is −15.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Broncus Holding Corp (2216)?
The operating margin of Broncus Holding Corp is 818% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Broncus Holding Corp (2216)?
Revenue at Broncus Holding Corp is growing −55.4% versus a year earlier (3y avg −73.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Broncus Holding Corp (2216) generate?
The free cash flow of Broncus Holding Corp is −10.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Broncus Holding Corp (2216) hold?
Broncus Holding Corp holds more cash than debt, 31.9M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Broncus Holding Corp in the live analysis
One click puts Broncus Holding Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
